Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
5.49
+0.07 (1.29%)
At close: Jun 4, 2025, 4:00 PM
5.53
+0.04 (0.73%)
After-hours: Jun 4, 2025, 7:59 PM EDT
Altimmune Revenue
Altimmune had revenue of $5.00K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $20.00K, down -95.12% year-over-year. In the year 2024, Altimmune had annual revenue of $20.00K, down -95.31%.
Revenue (ttm)
$20.00K
Revenue Growth
-95.12%
P/S Ratio
22,263.86
Revenue / Employee
$339
Employees
59
Market Cap
445.28M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
Dec 31, 2023 | 426.00K | 494.00K | -726.47% |
Dec 31, 2022 | -68.00K | -4.48M | -101.54% |
Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ALT News
- 2 days ago - Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential - Seeking Alpha
- 6 days ago - Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity - Seeking Alpha
- 16 days ago - Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) - GlobeNewsWire
- 21 days ago - Altimmune to Participate at Two Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Altimmune Announces First Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 22 days ago - Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital - GlobeNewsWire
- 27 days ago - Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ - GlobeNewsWire